Crossmark

A novel measure of AV-conduction predicts clinical outcomes and benefit from CRT-D in non-LBBB patients with wide QRS and a low left ventricular ejection fraction

Crossref DOI link: https://doi.org/10.1007/s00392-025-02731-3

Published Online: 2025-08-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beierle, Anika Sophie

Zareba, Wojciech

Auge, Richard E.

Rosero, Spencer Z.

McNitt, Scott

Knebel, Fabian

Stockburger, Martin A.

Kutyifa, Valentina https://orcid.org/0000-0002-0016-289X
,
License Information

Text and Data Mining valid from 2025-08-20

Version of Record valid from 2025-08-20
More Information

Article History

Received: 13 May 2025

Accepted: 15 July 2025

First Online: 20 August 2025

Declarations

:

: Dr. Valentina Kutyifa reports research grants from Boston Scientific, ZOLL, Biotronik, Spire Inc., NIH, and consultant/speaker fees from ZOLL, Biotronik, Medtronic, Abbott. Martin Stockburger was supported by research grants by Biotronik, Boston Scientific, Medtronic, and Sorin Group and is an educational speaker for Medtronic and Biotronik. Wojciech Zareba received research grant from Boston Scientific. Anika Beierle, Richard Auge, Fabian Knebel and Scott McNitt have nothing to disclose.Clinical trial registration:

Document is current

Any future updates will be listed below